A chat with a veteran biotech investor on investment cycles | 直播

全球首款siRNA药物已成“弃子”,上市才五年,就被里外嫌弃,siRNA龙头的下一步怎么走……

SAPA-GP Webinar

SAPA-GP Webinar welcome you to attend:

BioVerse: Where Science Sparks Business【Episode 004】

A chat with a veteran biotech investor on investment cycles | 直播

Introduction 

In the throes of a harsh capital winter, the biotech industry faces layoffs, delistings, and mergers, dominating today’s headlines. When will this financial chill end? How does it compare to previous winters? Explore the biotech survival handbook and gain insights from Les Funtleyder on navigating this challenging landscape. 

Join us on EP004 to weather the storm and preserve energy forbrighter days in the global biotech industry. 

 

Speaker:

Les Funtleyder

CFO, Investor, Professor, Author

Moderator:

Leon ‘Jun’ Tang, Ph.D., M.S.

Founder of InScienceWeTrust

Community

 

Organizers:

A chat with a veteran biotech investor on investment cycles | 直播
 

Partners & Collaborators:

A chat with a veteran biotech investor on investment cycles | 直播
 

| /

Registration 

Date and Time:

 

Wednesday, Dec 13, 8:30 AM to 9:30 AM (EST)

Wednesday, Dec 13, 9:30 PM to 10:30 PM (北京时间)

Speaker’s Bio

Les FuntleyderCFO, Investor

Professor, Author

A chat with a veteran biotech investor on investment cycles | 直播
上下滑动查看完整介绍

Mr. Funtleyder has a 20-year track record of healthcare investing and is currently a Healthcare Portfolio Manager at E Squared Capital Management where he is responsible for conducting fundamental and valuation analysis of public and private companies within the healthcare industry. While at E squared Les has had five IPO exits including serving as CFO of one of the portfolio companies. 

Prior to E Squared, Mr. Funtleyder was the Director of Strategic Investments and Communications for Opko Health. In this role he participated in over $2 billion in transactions including acquisitions, strategic investments, and licensing deals. He also led all corporate and product communication efforts for the $5 billion company. 

Les was a long-time portfolio manager and healthcare strategist for the Miller Tabak Health Care Transformation Fund (Symbol: MTHFX) a mutual fund dedicated to investing in transformative healthcare companies. 

He joined Miller Tabak, after managing a healthcare portfolio for Provident Advisors, a hedge fund in Minneapolis, Minnesota. Before joining Provident, Les worked as a medical device analyst at UBS Warburg. He also covered Biotechnology stocks at Bigelow and Company. His industry experience includes directing clinical and business research at Innovative Health Solution, a joint venture of Merck and Wyeth, and as a consultant to HMOs and hospitals for Coopers & Lybrand and Health Strategies Group. He started his healthcare career at Empire Blue Cross/Blue Shield where he developed his approach to determining how products and services should get reimbursed, a skill that is vital in making healthcare companies successful. 

Mr. Funtleyder wrote Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services (McGraw Hill), which bridges the gap between health reform, innovation and investing. He is widely quoted in the Wall Street Journal, the New York Times, and the Financial Times, and is a frequent guest on CNBC, Bloomberg and NPR for his perspective on the healthcare sector and its constituent companies. He is also a consulting partner to Bluecloud Health, a Sub-Saharan healthcare private equity fund and an advisor to Zentalya, a venture capital firm focused on South American healthcare. He currently sits on the Board of Directors for Applied Therapeutics (NASDAQ: APLT) and Reviva Pharma (NASDAQ: RVPH).

Lastly, Les is currently an Adjunct Professor of Public Health at Columbia University. Les earned his Master of Public Health from Columbia University Mailman School of Public Health, and studied English and Economics at Tulane University.

封面图来源:123rf

A chat with a veteran biotech investor on investment cycles | 直播

A chat with a veteran biotech investor on investment cycles | 直播

本篇文章来源于微信公众号: 药时代

发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2023年12月12日 17:26
下一篇 2023年12月13日 16:22

相关推荐

公众号
公众号
分享本页
返回顶部
开门红!药时代成功促成中美两家药企达成合作!了解详情